Country: United States
Language: English
Source: NLM (National Library of Medicine)
diatrizoate meglumine (UNII: 3X9MR4N98U) (diatrizoic acid - UNII:5UVC90J1LK)
BRACCO DIAGNOSTICS INC
INTRAVENOUS
PRESCRIPTION DRUG
This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.
Cystografin (Diatrizoate Meglumine Injection USP 30%) is available in 200 mL and 400 mL bottles containing 100 mL and 300 mL of Cystografin respectively with sufficient capacity for dilution up to 167 mL and 350 mL respectively. Store at 20-25°C (68-77°F) [See USP]. Protect from light. Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is also available, as a 300 mL fill in a 400 mL bottle.
New Drug Application
CYSTOGRAFIN- DIATRIZOATE MEGLUMINE INJECTION, SOLUTION BRACCO DIAGNOSTICS INC ---------- CYSTOGRAFIN DIATRIZOATE MEGLUMINE INJECTION USP 30% FOR RETROGRADE CYSTOURETHROGRAPHY NOT INTENDED FOR INTRAVASCULAR INJECTION DESCRIPTION Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen. The preparation should be protected from strong light. INDICATION Cystografin is indicated for retrograde cystourethrography. CONTRAINDICATIONS This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid. WARNINGS Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents. A history of sensitivity to iodine _per se_ or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration. PRECAUTIONS Safe and effective use of this preparation depends upon proper dosage, correct technique, adequate precautions, and readiness for emergencies. Retrograde cystourethrography should be performed with caution in patients with a known active infectious process of the urinary tract. Sterile technique should be employed in administration. During administration, care should be taken to avoid excessive pressure, rapid or acute distention of the bladder, and trauma. Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards. PREGNANCY—TERATOGENIC EFFECTS: Animal reproduction studies have not been conducted with diatrizoate meglumine in Read the complete document